

CITATION REPORT

List of articles citing

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

DOI: 10.1016/j.medj.2021.04.003
Med, 2021, 2, 682-688.e4.

Source: <https://exaly.com/paper-pdf/80756768/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
104	Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. 2021 , 21, e29		4
103	Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination.		15
102	The Physiologic Response to COVID-19 Vaccination. 2021 ,		2
101	Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older.		13
100	Non-neutralizing secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon BNT162b2 vaccination.		2
99	Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease. 2021 ,		12
98	Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate.		8
97	Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study).		12
96	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. 2021 , 80, 1339-1344		78
95	A Peptide Vaccine Candidate Tailored to IndividualsSGenetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. 2021 , 12, 684152		1
94	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. 2021 , 13,		58
93	Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.		23
92	The importance of time post-vaccination in determining the decrease in vaccine efficacy against SARS-CoV-2 variants of concern.		2
91	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. 2021 , 63, 885-897		3
90	Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected.		2
89	Animal Coronavirus Diseases: Parallels with COVID-19 in Humans. 2021 , 13,		3
88	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. 2021 , 29, 1137-1150.e6		68

87	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. 2021 , 398, 121-130	133
86	A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults.	7
85	Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development.	
84	Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals. 2021 , 10, 2765-2776	17
83	Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. 2021 , 69, 576-583	11
82	Recent Advances in Aggregation-Induced Emission Materials and Their Biomedical and Healthcare Applications. 2021 , e2101055	7
81	Durability and Cross-Reactivity of Immune Responses Induced by an AS03 Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19.	0
80	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. 2021 , 36, 109570	29
79	Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer. 2021 , 154, 66-72	14
78	Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. 2021 , 12, 730051	2
77	Rapid induction of antigen-specific CD4 T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. 2021 , 54, 2133-2142.e3	117
76	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. 2021 , 131,	20
75	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. 2021 , 3, e789-e797	72
74	Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed. 2021 , 56, 103263	1
73	T cell immunity to SARS-CoV-2. 2021 , 101505	11
72	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.	1
71	Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men. 2021 , 10, 2141-2150	4
70	A Rapid and Simple Multiparameter Assay to Quantify Spike-Specific CD4 and CD8 T Cells after SARS-CoV-2 Vaccination: A Preliminary Report. 2021 , 9,	0

69	SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2.	1
68	BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype. 2021 , 6, eabl5344	32
67	Multibacillary leprosy unmasked by COVID-19 vaccination. 2021 ,	1
66	Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.	1
65	Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. 2021 ,	4
64	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. 2021 ,	49
63	Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.. 2021 , 9,	2
62	A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine. 2021 , 14, 421-426	3
61	SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron.. 2022 , 14,	17
60	Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.. 2022 ,	59
59	Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences.. 2022 , 10,	2
58	Differential immunogenicity of homologous versus heterologous boost in Ad26.COVS.S vaccine recipients.. <i>Med</i> , 2022 ,	31.7 4
57	Antibody Response to SARS-CoV-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation.. 2022 ,	0
56	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.. 2022 ,	2
55	COVID-19 Antibodies in Vaccinated Healthcare Workers: The Security Currency.. 2022 , 14, e23383	0
54	Identification of Potential SARS-CoV-2 CD8 T Cell Escape Mutants.. 2022 , 10,	0
53	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.	0
52	An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.. 2022 , 10,	0

51	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.. 2022 ,	1
50	mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship.. 2021 , 9,	2
49	Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination. 2021 , 100468	5
48	Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection.. 2021 , 17, e1009735	0
47	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands.. 2022 , 5, 49	0
46	Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination.. 2022 , 14,	1
45	Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response.. 2022 , 10,	2
44	Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients.. 2022 ,	0
43	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. 2022 ,	6
42	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. 2022 , 20, e3001609	0
41	Favorable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies.. 2022 ,	2
40	Inducing broad-based immunity against viruses with pandemic potential.. 2022 , 55, 738-748	0
39	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. 2022 , 80, 104062	2
38	Omicron reactive multi protein specific CD4 T cells defines cellular immune response induced by inactivated virus vaccines.	0
37	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. 2022 , 10, 909	0
36	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR.	2
35	Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.	3
34	Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients. 2022 , 10, 921	2

33	How to Evaluate COVID-19 Vaccine Effectiveness: An Examination of Antibody Production and T-Cell Response. 2022 , 12, 1401	
32	Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center. 9,	1
31	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. 13,	1
30	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. 1-27	0
29	Immunodeficiency syndromes differentially impact the functional spectrum of SARS-CoV-2-specific T cells elicited by mRNA vaccination. 2022 ,	1
28	Self-Reported Use of COVID-19 Immunologic Test Results to Inform Decisions About Daily Activities and COVID-19 Vaccination.	
27	Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2. 2022 , 10, 1117	0
26	Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. 13,	2
25	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. 2022 , 23, 8982	1
24	SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic.. 2022 ,	2
23	Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. 2022 , 23, 10679	0
22	Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers. 2022 , 12, 1318	1
21	SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9-months longitudinal study. 2022 , 12,	3
20	Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination. 13,	0
19	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. 2022 , 10, 1784	0
18	Type 1 lepra reaction induced by a COVID -19 vaccine.	0
17	Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19. 2022 , 13,	1
16	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. 2022 , 7,	0

15	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. 13,	0
14	Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH. 2022 , 23, 14988	1
13	A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. 2022 , 7,	0
12	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. 2022 , 28, 211-222	0
11	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. 2023 , 11, 51	2
10	Early induction of anti-Spike binding antibodies and T cells confer protection against COVID-19 in children during an Omicron wave.	0
9	T Cell Responses to SARS-CoV-2. 2023 , 41,	1
8	Employing T-Cell Memory to Effectively Target SARS-CoV-2. 2023 , 12, 301	0
7	Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers. 14,	0
6	Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents. 14,	0
5	Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines. 2023 , 95,	1
4	An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial. 14,	0
3	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. 2023 , 24, 5944	0
2	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. 2023 , 14,	0
1	COVID-19 vaccine induced t-cell immunity influenced by age and comorbidities. 2023 , 10, 40-41	0